Cancer & Disease Research
Monoclonal antibodies reduced COVID-19 hospitalization, death risk by a third: Study
During the COVID-19 pandemic, healthcare providers nationwide administered an evolving array of monoclonal antibody treatments, previously untested on such a large scale. A study, published Monday in the Annals of Internal Medicine, showed that this effort saved lives. Read More
CAR T-cells show preliminary efficacy, safety as solid-tumor treatment
Researchers presented phase I/II preliminary clinical trial data demonstrating the safety and efficacy of a new CAR T-cell therapy that can be used as either a monotherapy or a combination therapy to treat Claudin 6-positive solid tumors. The findings were presented at the American Association for Cancer Research Annual Meeting 2022 in New Orleans. Read More
Scientists improve ADC development with mix of experimental, computational tools
BOSTON -- Greg Thurber, PhD, professor at the University of Michigan explained how his lab is jointly using both experimental animal models and computational models to improve the overall speed and efficiency of drug development of antibody-drug conjugates (ADCs) to get more of the agents on the market. Thurber presented in a scientific session at the Society for Laboratory Automation and Screening (SLAS) 2022 International Conference and Expo. Read More
Nucleosomes dictate the histone code
The histone code concept needs to be redefined at the nucleosomal level, according to Michael-Christopher Keogh, PhD, chief scientific officer of EpiCypher. During a live webinar, Keogh shared information about the tools that are required to critically re-evaluate the genomic distribution and regulatory function(s) of histone post-translational modification (PTMs). Read More
How one company is helping make complex medicines safer
Often, the most dangerous things in life are things that the human eye cannot see. This is true even for life-saving medicines. One company was founded to help the industry find these hidden particles and solve a key challenge in the development of complex drug products. Halo Labs’ CEO Rick Gordon spoke with ScienceBoard about how its low volume approach is providing a critical service for the drug development industry. Read More
Bio-Rad develops antidaratumumab antibodies for drug monitoring
Bio-Rad Laboratories has launched a range of antidaratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars, according to the company. Read More
Do advanced therapies have a place in women's health?
Change may be on the horizon for the traditionally competitive and underinvested field of women's health, according to scientific experts in the field. With increased awareness, fast-paced innovation, and appropriate investment, the sector is ripe for progress. ScienceBoard spoke with Martin Lehr, CEO of Context Therapeutics, as part of Biotech Finance Month 2022. Read More
COVID-19-related sales remain strong for lab tool firms in 2021
Laboratory tool companies have been among the biggest beneficiaries of U.S. government COVID-19-related spending on coronavirus testing and vaccine R&D and manufacturing. COVID-19-related sales have propelled sales at Thermo Fisher Scientific, Danaher, and PerkinElmer, already three of the world's largest scientific instrument and reagent providers. Read More
New 'antibody-decorated nanocrystals' target cancer cells
Researchers have bioengineered a metal-organic framework antibody drug delivery system that has the potential to fast-track personalized therapies for cancer and other diseases. The findings were published December 7 in the journal Advanced Materials. Read More
1
Conferences
Science Briefs
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter